TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16167250

Group type: EXPERIMENTAL
Intervention: Hereditary nonpolyposis colorectal cancer (HNPCC) patients
Number of subjects: 167
Study: 11914996

Group type: EXPERIMENTAL
Intervention: ertapenem
Number of subjects: 502

Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 502
Study: 11424510

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (200 mg ferrous fumarate and 200 mg folic acid) for 24 weeks
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 280
Study: 9764453

Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Transurethral electrovaporization (TVP)
Number of subjects: 31
Study: 7828249

Group type: EXPERIMENTAL
Intervention: Arterial hyperoxia (PaO2 > 200 mmHg) at PaCO2 of 25 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arterial hyperoxia (PaO2 > 200 mmHg) at PaCO2 of 30 mmHg
Number of subjects: 12
Study: 3134786

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7828347

Group type: EXPERIMENTAL
Intervention: Pamidronate administered every 14 days (60 mg/dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pamidronate administered every 21 days (60 mg/dose)
Number of subjects: 34
Study: 355033

Group type: EXPERIMENTAL
Intervention: Nicotinic acid compound
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31397487

Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 4570

Group type: COMPARATOR
Intervention: 12-month aspirin monotherapy following 12-month DAPT
Number of subjects: 4570
Study: 30597946

Group type: EXPERIMENTAL
Intervention: Martial arts based psycho-social intervention
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study: 26285023

Group type: EXPERIMENTAL
Intervention: 150 mg · kg(‐1) body mass TYR
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 75 mg · kg(‐1) body mass TYR
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (sugar-free drink)
Number of subjects: 21
Study: 24472321

Group type: EXPERIMENTAL
Intervention: Four isocaloric eating episodes at T0, T60, T120, and T180min (F4)
Number of subjects: 17

Group type: COMPARATOR
Intervention: One eating episode at T0 (F1)
Number of subjects: 17
Study: 22281448

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Intervention (BSI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19878043

Group type: EXPERIMENTAL
Intervention: Fluroshield (sealant with fluoride)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aegis (sealant with ACP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Experimental sealant with fluoride (ESF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Experimental sealant with fluoride/ACP (ACP-F)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (demineralized enamel slab)
Number of subjects: 10
Study: 17510766

Group type: EXPERIMENTAL
Intervention: Kugel procedure
Number of subjects: 172

Group type: COMPARATOR
Intervention: Lichtenstein procedure
Number of subjects: 172
Study: 16319785

Group type: EXPERIMENTAL
Intervention: Iyengar yoga classes (2 weekly 90-min sessions for 3 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 24
Study: 12395330

Group type: EXPERIMENTAL
Intervention: VPA-985 300 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VPA-985 (doses 100 mg or greater)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VPA-985
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VPA-985 (100 mg to 200 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10091762

Group type: EXPERIMENTAL
Intervention: Dose-intense arm: cisplatin 35 mg/m2 and etoposide 200 mg/m2 on Days 1-3 every 4 weeks.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Dose-dense arm: same chemotherapy schedule every 3 weeks plus 5 microg/kg of rhGM-CSF on Days 4-13.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Dose-dense arm
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dose-intense arm
Number of subjects: 123
Study: 7584517

Group type: EXPERIMENTAL
Intervention: Gas mixture with reduced oxygen content (H; FIO2: 0.14)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal air (N)
Number of subjects: 15
Study: 2247670

Group type: EXPERIMENTAL
Intervention: Intratracheal cocaine (4 ml, 2.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intratracheal lignocaine (4 ml, 4%)
Number of subjects: 60
Study: 7392404

Group type: EXPERIMENTAL
Intervention: Long-term intensive physical training according to a special program (Group 2)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 53
Study: 30332674

Group type: EXPERIMENTAL
Intervention: 577-nm multispot laser with a 20-ms pulse duration
Number of subjects: 41

Group type: COMPARATOR
Intervention: 532-nm single-spot laser with a 100-ms pulse duration
Number of subjects: 41
Study: 29267506

Group type: EXPERIMENTAL
Intervention: Arndt-endobronchial blocker plus laryngeal mask airway (LMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Left-sided double-lumen endobronchial tube (L-DLT)
Number of subjects: 80
Study: 25730811

Group type: EXPERIMENTAL
Intervention: Lidocaine 1mg/kg (Group III)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5mg/kg (Group IV)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, Group I)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5mg/kg (Group II)
Number of subjects: 400
Study: 23855898

Group type: EXPERIMENTAL
Intervention: Baska mask
Number of subjects: 150

Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 150
Study: 21550218

Group type: EXPERIMENTAL
Intervention: Cocoa powder with 500 mL of skimmed milk/day (C + M)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Only 500 mL/day of skimmed milk (M)
Number of subjects: 42
Study: 19698903

Group type: EXPERIMENTAL
Intervention: Adjunctive quetiapine with lithium or valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + lithium/valproate
Number of subjects: 0
Study: 17450257

Group type: EXPERIMENTAL
Intervention: CYFRA 21-1 assay (immunoradiometric assay)
Number of subjects: 96
Study: 15226463

Group type: EXPERIMENTAL
Intervention: Very low-fat diet (VLF, 12% energy from fat)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High monounsaturated fat diet (HIMO, 35% energy from fat)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Very low-fat diet (VLF)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High monounsaturated fat diet (HIMO)
Number of subjects: 62
Study: 11860401

Group type: EXPERIMENTAL
Intervention: Single subject trial
Number of subjects: 0
Study: 10221740

Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8619572

Group type: EXPERIMENTAL
Intervention: Rimantadine 100 mg/day
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Rimantadine 200 mg/day
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Combined Rimantadine (100 mg/day and 200 mg/day)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study: 2153185

Group type: EXPERIMENTAL
Intervention: CRB 87 (10(6.6)‐10(7.6) TCID50)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CRB 87 (10(7.6) TCID50)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wild-type influenza B/Texas/1/84 (10(3.9)‐10(7.1) TCID50)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Wild-type virus (10(7.1) TCID50)
Number of subjects: 29
Study: 320918

Group type: EXPERIMENTAL
Intervention: Food extract injection therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29321031

Group type: EXPERIMENTAL
Intervention: Deprescribing preventive cardiovascular medication (intervention group)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1067
Study: 26978860

Group type: EXPERIMENTAL
Intervention: DAMA+SOC
Number of subjects: 29

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 29
Study: 24619957

Group type: EXPERIMENTAL
Intervention: 6-hour self-directed workbook intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 41
Study: 21925957

Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) monotherapy to a prescribed dose of 144Gy
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: D(90) > 140Gy compared with lower doses
Number of subjects: 1466

Group type: EXPERIMENTAL
Intervention: Neoadjuvant and concurrent androgen deprivation therapy
Number of subjects: 1466
Study: 20444631

Group type: EXPERIMENTAL
Intervention: Psychosocial-based interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported disability measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessed psychological outcomes
Number of subjects: 0
Study: 17275225

Group type: EXPERIMENTAL
Intervention: Herbal product containing 72 mg/dose of isoflavones (BIO)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16138529

Group type: EXPERIMENTAL
Intervention: Family Involvement in Care (FIC) protocol
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 12005117

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonanoic acid (NON)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 12
Study: 9527293

Group type: EXPERIMENTAL
Intervention: GP diagnostics
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Sentinel Stations criteria
Number of subjects: 1838

Group type: COMPARATOR
Intervention: ICHPPC-2 criteria
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Combination of symptoms (fever, coughing, acute onset)
Number of subjects: 1838
Study: 8586319

Group type: EXPERIMENTAL
Intervention: UF heparin, 10,000 IU s.c., b.d.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fragmin, 5,000 IU anti-factor Xa s.c., b.d.
Number of subjects: 66
Study: 2093079

Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alizapride + Dexamethasone
Number of subjects: 0
Study: 359098

Group type: EXPERIMENTAL
Intervention: High dose spinal irradiation (2400 rads) without intrathecal methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 given intravenously every 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four 12-week courses of chemotherapy after eight courses (total duration two years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender comparison (Girls vs Boys)
Number of subjects: 0
Study: 30852728

Group type: EXPERIMENTAL
Intervention: mHealth intervention (WeTest) delivered via WeChat app; participants received two oral HIVST kits and access to a private WeChat group with app-based messages and referrals to health services.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received two oral HIVST kits only.
Number of subjects: 100
Study: 28044049

Group type: EXPERIMENTAL
Intervention: Wahakura
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bassinet
Number of subjects: 200
Study: 25996255

Group type: EXPERIMENTAL
Intervention: Patient decision support
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 24377211

Group type: EXPERIMENTAL
Intervention: Deep puncture group (electroacupuncture at Tianshu ST 25, needle depth 20-65 mm)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Western medication group (lactulose oral liquid)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Shallow puncture group (electroacupuncture at Tianshu ST 25, needle depth 5-8 mm)
Number of subjects: 128
Study: 21281407

Group type: EXPERIMENTAL
Intervention: co-trimoxazole (cotox)
Number of subjects: 600

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600
Study: 19433666

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 120 mg twice a day
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study: 16144819

Group type: EXPERIMENTAL
Intervention: Weight loss (50% reduction of overweight/15% absolute weight loss, using a very low-calorie diet)
Number of subjects: 11
Study: 14613263

Group type: EXPERIMENTAL
Intervention: Data-driven outcomes
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: DMARDs
Number of subjects: 264

Group type: COMPARATOR
Intervention: Coxib versus placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: ACR20
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: DDAS
Number of subjects: 264
Study: 11007567

Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9173422

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms b.i.d. by MDI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Theophylline (Uniphyllin; 600 mg nocte orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 16
Study: 7877825

Group type: EXPERIMENTAL
Intervention: 131I-HIPDM
Number of subjects: 0
Study: 3362554

Group type: EXPERIMENTAL
Intervention: Orally administered ethyl alcohol (1 ml/kg of 100% ethyl alcohol + 1 ml/kg tonic water)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.17 mg/kg s.q. morphine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pharmacologically active placebo (atropine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Totally inactive placebo (saline)
Number of subjects: 18
Study: 30298371

Group type: EXPERIMENTAL
Intervention: Method A (IQ-SPECT)
Number of subjects: 55
Study: 29038157

Group type: EXPERIMENTAL
Intervention: Increased plasma ferritin concentration (doubling)
Number of subjects: 62537

Group type: EXPERIMENTAL
Intervention: C282Y/C282Y genotype
Number of subjects: 62537
Study: 24476530

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention involving a dedicated Generic Rehabilitation Assistant (GRA) trained in physiotherapy, dietetics, occupational therapy, and speech/language therapy, from ICU discharge to 3 months post-discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 22575311

Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTE)
Number of subjects: 3428
Study: 20739378

Group type: EXPERIMENTAL
Intervention: Piragliatin 25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Piragliatin 100 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18999909

Group type: EXPERIMENTAL
Intervention: Influenza mailing intervention
Number of subjects: 134791

Group type: EXPERIMENTAL
Intervention: Nurse advice service mailing intervention
Number of subjects: 134791

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 134791
Study: 15695785

Group type: EXPERIMENTAL
Intervention: Sucking lemon candy started within 1 hour after radioiodine ingestion (group A)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sucking lemon candy withheld until 24 hours after radioiodine ingestion (group B)
Number of subjects: 230
Study: 14669165

Group type: EXPERIMENTAL
Intervention: Low adiponectin levels
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lowest tertile of adiponectin
Number of subjects: 101
Study: 10767728

Group type: EXPERIMENTAL
Intervention: Citalopram 20-40 mg/day
Number of subjects: 336

Group type: COMPARATOR
Intervention: Mianserin 30-60 mg/day
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 336

Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Citalopram and Mianserin
Number of subjects: 336
Study: 7564037

Group type: EXPERIMENTAL
Intervention: Epidural injection of buprenorphine (intermittent injection before awakening from anesthesia)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Epidural injection of buprenorphine (continuous injection)
Number of subjects: 46
Study: 2117332

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms (n = 51)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms (n = 53)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo (n = 103)
Number of subjects: 207
Study: 6113683

Group type: EXPERIMENTAL
Intervention: 0.6 mg l-hyoscyamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: 50 mg trimipramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: 150 mg ranitidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31805989

Group type: EXPERIMENTAL
Intervention: PF-06650833 IR 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06650833 MR 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06650833 IR 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06650833 IR <750 mg and MR 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06650833 IR ≥250 mg and MR 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF-06650833 IR 25 to 750 mg, IR 1000 mg four times per day, IR 330 mg three times per day, MR 300 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-06650833
Number of subjects: 0
Study: 27437568

Group type: EXPERIMENTAL
Intervention: Preoperative TEAS combined with intraoperative TEAS (group TTS)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Preoperative TEAS combined with postoperative TEAS (group TST)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Sham TEAS (group SSS)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Preoperative TEAS (group TSS)
Number of subjects: 380
Study: 26370288

Group type: EXPERIMENTAL
Intervention: Writing Aid Tool (WAT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no reminders)
Number of subjects: 41
Study: 24041301

Group type: EXPERIMENTAL
Intervention: Intelligence measure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious strategies engagement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious influences removal
Number of subjects: 0
Study: 21435854

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2
Number of subjects: 8053

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 2 × 2
Number of subjects: 8053

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (1 × 2)
Number of subjects: 8053

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (2 × 2)
Number of subjects: 8053

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 8053

Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 8053
Study: 19218880

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 609

Group type: COMPARATOR
Intervention: Side position
Number of subjects: 609
Study: 17940604

Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 15503754

Group type: EXPERIMENTAL
Intervention: Teacher-centered instruction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Student-centered instruction
Number of subjects: 40
Study: 11324212

Group type: EXPERIMENTAL
Intervention: Prostheses connected to ball abutments after a maximum of 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Implants loaded with an overdenture connected with ball abutments after 3 months (control group)
Number of subjects: 21
Study: 9270507

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.05%
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.01%
Number of subjects: 298
Study: 8288696

Group type: EXPERIMENTAL
Intervention: Decapeptyl (3.75 mg, im, every 28 days for 6 months) with estrogen (conjugated equine estrogens, 0.625 mg for 21 days and medroxyprogesterone acetate, 10 mg for 10 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Decapeptyl (3.75 mg, im, every 28 days for 6 months) alone
Number of subjects: 22
Study: 3293255

Group type: EXPERIMENTAL
Intervention: Combined therapy with small doses of prednisolone (5 mg) and chlorambucil (4 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate and ibuprofen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (local therapy of the parotid glands)
Number of subjects: 80
Study: 30685440

Group type: EXPERIMENTAL
Intervention: LDL triglycerides
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: Low hepatic lipase activity
Number of subjects: 3140
Study: 28561554

Group type: EXPERIMENTAL
Intervention: Fluoridated milk with 0.185 mg F
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluoridated milk with 0.375 mg F
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (no fluoride added milk) with non-fluoride toothpaste
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1,000 ppm)
Number of subjects: 9
Study: 26780018

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg, twice daily starting on the day of surgery until the seventh day post-operatively or discharge
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (historical patients)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Celecoxib treatment
Number of subjects: 252
Study: 23377833

Group type: EXPERIMENTAL
Intervention: Exercise only (EX)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI) after exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CON) - no exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 11
Study: 21943384

Group type: EXPERIMENTAL
Intervention: Integrated TB DOTS plus smoking cessation intervention (SCIDOTS group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional TB DOTS alone (DOTS group)
Number of subjects: 120
Study: 19064841

Group type: COMPARATOR
Intervention: Atropine eyedrops (weekend use)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Patching of the sound eye (2 hours per day)
Number of subjects: 193